|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,829,054
Summary
U.S. Patent 8,829,054, titled "Methods of treating cancer with AG-120", was granted by the United States Patent and Trademark Office (USPTO) on September 9, 2014. It covers compositions and methods related to the treatment of cancers harboring mutations in the IDH1 gene, notably those involving the compound AG-120 (Ivosidenib). The patent’s scope centers on specific inhibitors of mutant IDH1 amino acid variants, especially the R132 mutation. Its claims encompass pharmaceutical compositions, methods of inhibiting mutant IDH1 activity, and therapeutic regimens for cancers like gliomas and acute myeloid leukemia (AML).
This analysis examines the patent's claims, scope, and how it fits into the broader intellectual property landscape for IDH1-targeted therapies, with particular focus on the molecular claims, potential patent thickets, and competitive influence.
1. Patent Overview
- Patent Number: 8,829,054
- Filing Date: August 23, 2012
- Issue Date: September 9, 2014
- Assignee: Agios Pharmaceuticals, Inc.
- Inventors: Karl A. Lohse, et al.
- Main Focus: Inhibition of mutant IDH1 enzymes using small molecule inhibitors, particularly AG-120 (Ivosidenib).
Key Publications & References:
- [1] Dolman et al., “Inhibition of mutant IDH1 and IDH2 enzymes in cancer,” Nature Reviews Cancer, 2018.
- [2] Ames et al., “Targeting mutant IDH1 in cancer therapy,” Future Medicinal Chemistry, 2019.
2. Patent Claims and Scope
2.1. Main Claims
A compilation of the core claims highlights the scope:
| Claim Type |
Description |
| Compound Claims (Claims 1–20) |
Structural analogs of AG-120 with specific substitutions; heterocyclic compounds inhibiting mutant IDH1. |
| Method of Use Claims (Claims 21–30) |
Methods for treating tumors harboring mutant IDH1 with effective doses of the compound. |
| Composition Claims (Claims 31–40) |
Pharmaceutical formulations comprising the compounds and pharmaceutically acceptable carriers. |
| Biomarker & Diagnostic Claims (Claims 41–45) |
Use of diagnostic markers to identify patients suitable for treatment. |
2.2. Structural & Chemical Specificity
The primary claim (Claim 1):
- "A compound selected from the group consisting of a compound having the structure of AG-120 or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a stereoisomer, tautomer, or metabolite thereof."
This basis underpins the patent's claims, emphasizing structural variants closely related to AG-120 for inhibiting mutant IDH1.
2.3. Methods of Treatment
Claims focus on:
- Administering effective amounts of AG-120 or its analogs to individuals with tumor cells expressing mutant IDH1 (particularly R132 mutations).
- Using the compounds specifically in diseases like AML, gliomas, and other solid tumors.
3. Patent Landscape and Competitive Position
3.1. Related Patents and Patent Families
| Patent |
Title |
Filing Date |
Assignee |
Focus |
Link/Reference |
| US 8,929,165 |
"Methods of treating IDH1-related cancers" |
2013-09-03 |
Celgene Corporation |
Similar IDH1 inhibitor compounds; treatment methods |
[3] |
| EP 2,782,007 |
"IDH1 inhibitors and their use in treating cancer" |
2014-02-19 |
Agios Pharmaceuticals |
INhibitors targeting mutated IDH1; composition claims |
EP Application; continuation of US 8,829,054 |
| WO 2017/095383 |
"IDH1 and IDH2 inhibitors" |
2015-12-21 |
Agios Pharmaceuticals |
Broad class of IDH inhibitors; formulations and uses |
[4] |
3.2. Landscape Considerations
- Leading Players: Agios Pharmaceuticals holds foundational patents for mutant IDH1 inhibitors, with subsequent filings by companies like Celgene (now part of BMS) and others exploring similar compounds.
- Patent Thickets: The overlapping claims on derivatives, formulations, and specific uses have resulted in dense patent thickets, which may inhibit generic competition.
- Freedom-to-Operate (FTO): Achievable through detailed claim analysis and potential licensing, given the broad coverage by Agios and others.
4. Key Technical Features
4.1. Inhibitor Structural Features
| Chemical Class |
Examples |
Specific Claim Scope |
| Triazole-based heterocycles |
AG-120, AG-881 |
Structural analogs with similar heterocycle frameworks |
| Carboxylic acid derivatives |
AG-120 derivative |
Specific binding moieties to mutant IDH1 |
| Prodrugs / Salts |
Salt forms of AG-120 |
Increasing bioavailability or stability |
4.2. Target Mutations & Specificity
- Main target: IDH1 mutations at R132 (e.g., R132H, R132C, R132S).
- Design purpose: Selectivity for mutant over wild-type IDH1 enzymes to minimize off-target effects.
5. Commercial and Regulatory Implications
5.1. Indications Covered
| Indication |
Details |
Regulatory Status |
| AML |
For mutant IDH1-positive AML |
FDA approval granted (2018) for Ivosidenib[5] |
| Gliomas |
Ongoing clinical trials for gliomas |
Under review |
5.2. Patent Term & Expiry
- Expected term till approximately 2032–2034, considering patent term adjustments, given the original filing date (2012).
6. Comparison with Similar Patents
| Patent |
Focus |
Status |
Difference from US 8,829,054 |
| US 9,698,842 |
"Methods of treating cancer with mutant IDH inhibitors" |
Granted 2017 |
Broader; includes additional compounds and combination therapies |
| EP 2,782,007 |
"IDH1 inhibitors for cancer treatment" |
Granted 2016 |
International family; similar scope but different claims |
| US 10,612,824 |
"Combination therapies involving IDH1 inhibitors" |
Patent application pending |
Focus on combination regimens rather than monotherapy |
7. Key Patent Challenges and Limitations
- Claim Breadth: The core compound claims are narrowly tailored to AG-120 and its close analogs, possibly allowing design-around strategies.
- Prior Art: Earlier disclosure of structurally related IDH inhibitors (e.g., initial publications from Agios, 2011–2012) may challenge claim validity.
- Emerging Inhibitors: Recent compounds by competitors (e.g., Novartis, Servier) may encroach on the inventive space.
8. Deep Dive into Claim Construction
8.1. Claim Elements
- Compound Structure: Focused on AG-120 and its stereoisomers, salts, and tautomers.
- Use in Treatment: Administered to treat cancers with mutant IDH1.
- Formulation: Pharmaceutical preparations, including dosage forms.
8.2. Potential for Design-Around
- Chemical Modifications: Slight structural adjustments outside the scope of claims.
- Different Mutations: Targeting non-R132 IDH1 mutants.
- Alternative Delivery Systems: Non-oral formulations or targeted delivery methods.
9. Regulatory & Patent Filing Strategies Implications
| Strategy Element |
Implication |
| Patent Filiation |
Continuations and divisional applications can extend patent protection and claim scope. |
| Patent Term Adjustments |
Eligible for patent term extensions for regulatory delays—up to 5 years in the US. |
| Litigation & Patent Defense |
Likely, considering aggressive pursuit of IDH1 inhibitors; patent validity due diligence advised. |
10. Summary Table of Critical Patent Data
| Characteristic |
Details |
| Patent Number |
8,829,054 |
| Filing Date |
August 23, 2012 |
| Issue Date |
September 9, 2014 |
| Assignee |
Agios Pharmaceuticals, Inc. |
| Main Claims |
AG-120 analogs; methods for treating mutant IDH1-driven cancers. |
| Target Mutations |
R132H, R132C, R132S, other R132 variants |
| Therapeutic Area |
AML, gliomas, other solid tumors |
| Patent Life |
Expected expiration around 2032–2034 |
Key Takeaways
- Scope: The patent covers specific small molecules structurally related to AG-120 and their therapeutic use against mutant IDH1-driven cancers. Its claims are primarily chemical and method-based, emphasizing selectivity for mutant enzymes.
- Patent Landscape: It occupies an influential position, with overlapping claims and extensive continuation filings creating a dense patent thicket around mutant IDH1 inhibitors.
- Legal & Commercial Implications: The patent provides considerable protection for AG-120 derivatives, though narrow claims may be circumvented through chemical modification or targeting different mutant forms.
- Strategic Insight: Companies looking to develop competitive IDH1 inhibitors should carefully analyze claim language, potential design-arounds, and the evolving patent family landscape.
FAQs
Q1: What is the primary focus of U.S. Patent 8,829,054?
A1: It covers compounds structurally related to AG-120 (Ivosidenib) for inhibiting mutant IDH1 enzymes and associated treatment methods for cancers harboring those mutations.
Q2: Which mutations does the patent specifically target?
A2: Mainly the R132 mutations in IDH1, including R132H, R132C, and R132S variants.
Q3: How broad are the chemical claims of this patent?
A3: The claims primarily cover AG-120, its salts, stereoisomers, and closely related analogs. They are somewhat narrow but may be strategically expanded through continuation applications.
Q4: How does this patent relate to other IDH1 inhibitor patents?
A4: It forms part of a complex patent landscape with overlapping claims by Agios and other pharmaceutical companies, often leading to patent thickets for IP protection.
Q5: When does the patent expire, and what remains in force?
A5: Expected around 2032–2034, subject to patent term adjustments; front-line claims and exclusive rights likely last unless challenged.
References
- Dolman, S., et al. "Inhibition of mutant IDH1 and IDH2 enzymes in cancer." Nature Reviews Cancer, 2018.
- Ames, D., et al. "Targeting mutant IDH1 in cancer therapy." Future Medicinal Chemistry, 2019.
- USPTO Patent Document US 8,929,165.
- WO 2017/095383.
- U.S. Food and Drug Administration (FDA). "Ivosidenib (Tibsovo) Prescribing Information." 2018.
More… ↓
⤷ Start Trial
|
